Avacta Science10 Nov 2024 12:12
It was good to hear the audio version of the presentation -- Thanks to AS /previous management for securing the IP .
Also great to hear Avacta ambition to beome the leader in using FAP Chemistry / Cancer Biology for chemo drugs . Thought Curtis Rink very innovative -, some very bright folk in the Lab . Sounds like Avacta have the inhouse expertise / knowledge to drive this forward "Avacta technology unleashes powerful cancer-killing drugs selectively in the tumor"
(wonder if still using Tufts /Bach Biosciences services : Note not listed as a partner )
Hopefully Avacta stick to this pipeline plan - select the best candidate cancer types -enroll the patients and get on with it
The value is the technology hopefully partners be lining up to get access to the Trojan horse assets. .
----------------
Owning the IP assets do matter : ( mind you guess for the majority here SP is what counts fair enough might take a while though to see those inflection points )
Good luck everyone involved
----------------
"Seizing the market opportunity with strong intellectual property positions and laser focus
© AVACTA LIFE SCIENCES LIMITED 2024
Avacta has exclusive rights to the pre|CISION® and the Affimer® technology, including the collective IP of each individually and the combined franchise
This simple intellectual property position is at the core of our partnerships to develop innovative therapeutics, research tools and diagnostics
Avacta’s pre|CISION technology has the potential to address many solid tumor indications with high unmet need, with a
substantial market opportunity
Avacta has developed significant know-how and IP in the manufacturing of pre|CISION therapies which is combined with a low cost of goods for drug supply
Sign In
Follow the stocks
